AR057224A1 - Moleculas de anticuerpo que tienen especificidad para la il- 6 humana - Google Patents

Moleculas de anticuerpo que tienen especificidad para la il- 6 humana

Info

Publication number
AR057224A1
AR057224A1 ARP060105382A ARP060105382A AR057224A1 AR 057224 A1 AR057224 A1 AR 057224A1 AR P060105382 A ARP060105382 A AR P060105382A AR P060105382 A ARP060105382 A AR P060105382A AR 057224 A1 AR057224 A1 AR 057224A1
Authority
AR
Argentina
Prior art keywords
antibody molecules
specificity
human
producing
methods
Prior art date
Application number
ARP060105382A
Other languages
English (en)
Inventor
R E Gelinas
M C Singhal
Y Zhang
A G Popplewell
R Adams
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37714544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR057224(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of AR057224A1 publication Critical patent/AR057224A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente se relaciona con las moléculas de anticuerpo que tienen especificidad para determinantes antigénicos de la IL-6, los usos terapéuticos de las moléculas de anticuerpo y los métodos para producir dichas moléculas de anticuerpo.
ARP060105382A 2005-12-09 2006-12-06 Moleculas de anticuerpo que tienen especificidad para la il- 6 humana AR057224A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74892605P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
AR057224A1 true AR057224A1 (es) 2007-11-21

Family

ID=37714544

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105382A AR057224A1 (es) 2005-12-09 2006-12-06 Moleculas de anticuerpo que tienen especificidad para la il- 6 humana

Country Status (28)

Country Link
US (5) US8075889B2 (es)
EP (3) EP1960430B1 (es)
JP (1) JP5183484B2 (es)
KR (2) KR101413451B1 (es)
CN (1) CN101356194B (es)
AR (1) AR057224A1 (es)
AU (1) AU2006323490B2 (es)
BR (1) BRPI0619595B8 (es)
CA (1) CA2632628C (es)
DK (1) DK1960430T3 (es)
EA (1) EA018044B1 (es)
EC (1) ECSP088613A (es)
ES (1) ES2525325T3 (es)
HK (1) HK1125113A1 (es)
HR (1) HRP20141214T1 (es)
IL (2) IL191600A (es)
MY (1) MY147217A (es)
NO (1) NO344847B1 (es)
NZ (1) NZ569234A (es)
PE (1) PE20070998A1 (es)
PL (1) PL1960430T3 (es)
PT (1) PT1960430E (es)
RS (1) RS53708B1 (es)
SI (1) SI1960430T1 (es)
TW (1) TWI390035B (es)
UA (1) UA96141C2 (es)
WO (1) WO2007066082A1 (es)
ZA (1) ZA200804594B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
EP1960430B1 (en) 2005-12-09 2014-09-24 UCB Pharma S.A. Antibody molecules having specificity for human il-6
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
HUE025283T2 (en) 2007-08-02 2016-03-29 Gilead Biologics Inc LOX and LOX2 inhibitors and their use
WO2009140348A2 (en) 2008-05-13 2009-11-19 Novimmune Sa Anti-il-6/il-6r antibodies and methods of use thereof
CA2742786A1 (en) * 2008-11-13 2010-05-20 Femta Pharmaceuticals, Inc. Humanized anti-il-6 antibodies
AU2009323002B2 (en) 2008-11-25 2016-01-28 Vitaeris Inc. Antagonists of IL-6 to raise albumin and/or lower CRP
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
NZ598464A (en) * 2009-08-21 2014-07-25 Gilead Biologics Inc Methods and compositions for treatment of pulmonary fibrotic disorders
CA2771702A1 (en) 2009-08-21 2011-02-24 Gilead Biologics, Inc. Catalytic domains from lysyl oxidase and loxl2
KR20130008021A (ko) * 2010-02-04 2013-01-21 길리아드 바이오로직스, 인크. 리실 산화효소-유사 2 (ｌｏｘｌ2)에 결합하는 항체, 및 그를 위한 사용 방법
EP2643016A2 (en) 2010-11-23 2013-10-02 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
US9289467B2 (en) * 2011-08-10 2016-03-22 Case Western Reserve University Compositions and methods for treating bone conditions
US20130149351A1 (en) * 2011-12-09 2013-06-13 University Of Southern California Polymer scaffolds and their use in the treatment of vision loss
WO2013175276A1 (en) * 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
US9234035B2 (en) 2012-10-22 2016-01-12 Fountain Biopharma Inc. Antibodies to interleukin-6
US20150239970A1 (en) * 2012-10-25 2015-08-27 Medimmune, Llc Stable, Low Viscosity Antibody Formulation
CA3023089A1 (en) * 2016-05-05 2017-11-09 The Trustees Of The University Of Pennsylvania Dna monoclonal antibodies targeting il-6 and cd126
CN106413047A (zh) * 2016-10-31 2017-02-15 北京小米移动软件有限公司 智能设备接入无线网络的方法和装置
TWI716668B (zh) 2017-02-01 2021-01-21 耶魯大學 心臟衰竭及心腎症候群之精準治療
JP6950242B2 (ja) * 2017-03-31 2021-10-13 ブラザー工業株式会社 通信装置
MX2020006882A (es) 2018-01-05 2020-09-07 Novo Nordisk As Metodos para tratar inflamacion mediada por interleucina-6 sin inmunosupresion.
US11976123B2 (en) 2018-04-20 2024-05-07 Lyvgen Biopharma Holdings Limited Anti-CD40 antibodies and uses thereof
CN116063495A (zh) 2018-09-28 2023-05-05 礼进生物医药科技（上海）有限公司 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
CA3158527A1 (en) * 2019-10-23 2021-04-29 Lyvgen Biopharma Holdings Limited Anti-cd40 binding molecules and bi-specific antibodies comprising such

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
IL88375A (en) * 1988-11-14 1995-07-31 Yeda Res & Dev Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method
CA1341588C (en) * 1988-01-26 2009-01-06 Michel Revel Human ifn-beta2/i1-6, its purification and use
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1541682A3 (en) 1988-09-02 2005-07-06 Dyax Corp. Generation and selection of recombinant varied binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
EP0580737B1 (en) 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JP3614183B2 (ja) * 1993-05-31 2005-01-26 中外製薬株式会社 ヒトインターロイキン−６に対する再構成ヒト抗体
AU6808194A (en) * 1993-05-31 1994-12-20 Chugai Seiyaku Kabushiki Kaisha Reconstructed human antibody against human interleukin-6
FR2707882B1 (fr) * 1993-07-23 1997-08-01 Immunotech Sa Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant.
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
DK0744958T3 (da) 1994-01-31 2003-10-20 Univ Boston Polyklonale antistofbiblioteker
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
CA2284271C (en) * 1997-03-21 2012-05-08 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized t cell-mediated diseases comprising il-6 antagonist as an active ingredient
GB9812545D0 (en) 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
PT2308888T (pt) * 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
WO2004020633A1 (ja) * 2002-08-30 2004-03-11 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute ヒト抗ヒトインターロイキン−６抗体及び該抗体フラグメント
US7993864B2 (en) 2002-12-03 2011-08-09 Ucb Pharma S.A. Assay for identifying antibody producing cells
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
PL1644412T5 (pl) 2003-07-01 2019-01-31 Ucb Biopharma Sprl Modyfikowane fragmenty Fab przeciwciała
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
EP1960430B1 (en) * 2005-12-09 2014-09-24 UCB Pharma S.A. Antibody molecules having specificity for human il-6

Also Published As

Publication number Publication date
IL191600A0 (en) 2008-12-29
RS53708B1 (en) 2015-04-30
CN101356194A (zh) 2009-01-28
EA200801427A1 (ru) 2008-12-30
US9096668B2 (en) 2015-08-04
PL1960430T3 (pl) 2015-03-31
US20140024077A1 (en) 2014-01-23
CA2632628C (en) 2016-01-19
US20070154481A1 (en) 2007-07-05
KR101422523B1 (ko) 2014-07-24
NO20083066L (no) 2008-09-08
US9631015B2 (en) 2017-04-25
US20120183996A1 (en) 2012-07-19
TW200728466A (en) 2007-08-01
IL242434B (en) 2018-04-30
HK1125113A1 (en) 2009-07-31
EP2314626A1 (en) 2011-04-27
NZ569234A (en) 2011-07-29
PT1960430E (pt) 2015-01-05
UA96141C2 (ru) 2011-10-10
US20170182159A1 (en) 2017-06-29
BRPI0619595A2 (pt) 2011-10-04
AU2006323490B2 (en) 2012-05-24
MY147217A (en) 2012-11-14
CA2632628A1 (en) 2007-06-14
ECSP088613A (es) 2008-08-29
US8075889B2 (en) 2011-12-13
ES2525325T3 (es) 2014-12-22
KR20130100386A (ko) 2013-09-10
US8486662B2 (en) 2013-07-16
DK1960430T3 (da) 2015-01-05
EP1960430B1 (en) 2014-09-24
PE20070998A1 (es) 2007-10-09
IL191600A (en) 2015-11-30
JP5183484B2 (ja) 2013-04-17
JP2009518023A (ja) 2009-05-07
AU2006323490A1 (en) 2007-06-14
ZA200804594B (en) 2010-08-25
EP2336181A1 (en) 2011-06-22
TWI390035B (zh) 2013-03-21
SI1960430T1 (sl) 2015-01-30
US20160039929A1 (en) 2016-02-11
EA018044B1 (ru) 2013-05-30
NO344847B1 (no) 2020-05-25
KR101413451B1 (ko) 2014-07-10
BRPI0619595B8 (pt) 2022-12-13
BRPI0619595A8 (pt) 2019-01-15
KR20080077271A (ko) 2008-08-21
CN101356194B (zh) 2013-06-12
BRPI0619595B1 (pt) 2020-09-15
WO2007066082A1 (en) 2007-06-14
EP1960430A1 (en) 2008-08-27
HRP20141214T1 (hr) 2015-02-13

Similar Documents

Publication Publication Date Title
AR057224A1 (es) Moleculas de anticuerpo que tienen especificidad para la il- 6 humana
AR051484A1 (es) Moleculas de anticuerpo que tienen especificidad para la il - 17 humana
AR061538A1 (es) Moleculas de anticuerpo que se unen a la il-17 humana
ECSP14000329A (es) Moléculas que son anticuerpos con especificidad por ox40 humano
ECSP056014A (es) MOLÉCULAS DE ANTICUERPOS QUE TIENEN ESPECIFICIDAD PARA IL-1ß HUMANA
CY1121431T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για τον ανθρωπινο οχ40
UY32489A (es) Moléculas de anticuerpos que tienen especificidad de unión por il-13 humana
CO6781516A2 (es) Moléculas de anticuerpos que se unen a il-17a y il-17f
EA200900492A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
DOP2012000104A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
ECSP088778A (es) Formulacion de un anticuerpo monoclonal humano anti-igf-1r
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
ECSP11010840A (es) Anticuerpos anti-il-13 modificados, composiciones, métodos y usos
CO6331296A2 (es) Inmunoglobulinas de dominio variable dual y usos de las mismas
CO6420355A2 (es) Anticuerpos biespecíficos anti-erbb-3/anti-c-met
GT201200318A (es) Anticuerpos hacia gdf8 humano
UY31904A (es) Anticuerpos contra il-6 y sus usos
CR9558A (es) Formulaciones de quinina
CL2022001684A1 (es) Anticuerpo con especificidad de unión para il-13 humana
CY1115868T1 (el) Μορια αντισωματων που εχουν ειδικο χαρακτηρα για το ανθρωπινο il-6

Legal Events

Date Code Title Description
FG Grant, registration